Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia The ORION-2 Pilot Study
- 1 June 2020
- journal article
- letter
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 141 (22), 1829-1831
- https://doi.org/10.1161/CIRCULATIONAHA.119.044431
Abstract
No abstract availableThis publication has 2 references indexed in Scilit:
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialThe Lancet, 2014
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis SocietyEuropean Heart Journal, 2014